Appalachian Labs of WV LLC

Appalachian Labs of WV LLC was paid $10.99M by Medicaid between Dec 2019 and Dec 2024, across 45 billing codes. Its largest line is G0482, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed — 55% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in West Virginia

Rank by total paid#4 of 36

Median peer was paid$61K

This provider vs. median180×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2019	24	$104.74
2020	3,895	$121K
2021	52,262	$2.31M
2022	42,767	$2.18M
2023	70,443	$3.00M
2024incomplete	74,973	$3.38M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	55%	116,772	51,532	$6.05M
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	36%	71,619	39,343	$3.95M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	2.0%	7,104	3,758	$221K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	1.5%	3,905	2,550	$160K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	1.3%	1,630	1,372	$145K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	<1%	3,686	2,015	$49K
87529		<1%	1,359	1,235	$47K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	2,461	2,134	$30K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	1,359	1,235	$26K
87511		<1%	1,359	1,235	$26K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	1,359	1,235	$26K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	1,359	1,235	$26K

33 more codes

87481		<1%	297	$25K
86803		<1%	2,513	$18K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	1,202	$16K
84443	Thyroid stimulating hormone (TSH)	<1%	2,651	$15K
86317		<1%	1,945	$14K
80053	Comprehensive metabolic panel	<1%	3,369	$14K
80050	General health panel	<1%	473	$13K
87340		<1%	2,386	$12K
80061	Lipid panel	<1%	1,839	$12K
86708		<1%	1,974	$12K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	3,114	$9K
83036	Hemoglobin; glycosylated (A1C)	<1%	1,696	$9K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	375	$7K
87500		<1%	301	$5K
87641		<1%	301	$5K
87653		<1%	297	$5K
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	<1%	141	$5K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	133	$5K
86592		<1%	2,193	$5K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	91	$4K
84439		<1%	935	$4K
82607		<1%	479	$3K
83735		<1%	770	$2K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	141	$2K
87640		<1%	108	$2K
81025		<1%	333	$1K
84481		<1%	108	$754.80
83540		<1%	104	$328.68
82728		<1%	49	$288.02
84480		<1%	30	$232.16
82746		<1%	15	$118.57
84436		<1%	14	$57.92
81001		<1%	15	$16.74

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialREDDY, JOSEPH (PARTNER)

Same official

Other billing entities under REDDY, JOSEPH

Full network →

Provider	Location	Paid
Advanced Endoscopy Consultants	Santee, CA	$778K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.